Previous 10 | Next 10 |
2023-09-05 14:36:49 ET Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) were down more than 16% as of 2:15 p.m. on Tuesday. The pharmaceutical stock has been in decline for several months, and in May, it announced it was suing the federal government, saying the Food and Drug Admin...
2023-09-05 13:07:33 ET Gainers: Helius Medical Technologies ( HSDT ) +a55% . Novo Integrated Sciences ( NVOS ) +38% . Shengfeng Development Limited ( SFWL ) +29% . Cibus ( CBUS ) +28% . Cellectar Biosciences ( CLRB ) +28% . C...
2023-09-04 04:30:00 ET Summary For the week, the S&P 500 was up 2.5%. We are now just 1.6% below the 2023 high-water mark, set on July 31. The market entered a Golden Cross configuration on February 2, 2023. A recession remains a distinct possibility, especially if the Fed...
Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK , Se...
2023-09-01 18:33:42 ET More on Airbnb and Blackstone Airbnb: Upgrading To Hold, Headwinds Priced In How To Think About Airbnb Blackstone: Load Up Before It Recovers Its All-Time Highs (Rating Upgrade) Blackstone: Time For A Rating Downgrade Airbnb: Ev...
2023-07-31 03:07:28 ET Summary Vanda Pharmaceuticals' Q2 2023 financial performance shows a decline in sales due to generic competition, particularly for Hetlioz. VNDA is facing challenges with negative earnings per share projections and declining sales, leading to uncertainty abo...
2023-07-27 19:07:10 ET Vanda Pharmaceuticals Inc. (VNDA) Q2 2023 Earnings Call July 27, 2023 16:30 PM ET Company Participants Mihael H. Polymeropoulos - President, Chief Executive Officer and Chairman of the Board Kevin Moran - Senior Vice President, Chief Financial ...
2023-07-27 16:03:50 ET Vanda Pharmaceuticals press release ( NASDAQ: VNDA ): Q2 GAAP EPS of $0.03. Revenue of $46.06M (-28.5% Y/Y). 2023 Guidance: Given uncertainties surrounding the U.S. market for HETLIOZ ® for the treatment of Non-24 as a result of the ...
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results PR Newswire Q2 2023 total revenues were $46.1 million Total revenues in the first six months of 2023 were $108.6 million Vanda provides update on pipeline advancements and regulatory ...
2023-07-21 14:01:24 ET Summary Jazz Pharmaceuticals' share price has languished in FY'22 with a number of pressures on its Xywav label. The FDA has supported the competing Lumryz label, stating it is clinically superior to Xywav, chiefly due to its once-nightly dosing regimen. ...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...